A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

NCT04207086 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage III

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib

Sponsor

Melanoma Institute Australia

Collaborators

[object Object]